IFNA2 and melanoma: Low-dose pegylated IFN-α2b was evaluated against LDI in the European Association of Dermato-Oncology (EADO trial) that prospectively enrolled 896 patients with resected stage IIA-IIIB melanoma (T ≥ 1.5 mm, without clinically detectable nodal disease) in a phase III trial.